

March 2, 2016

Dear Manufacturers,

I am writing on behalf of University of Missouri Health Care (MUHC) (DSH260141) to inform manufacturers that MUHC recently underwent an audit by the Health Resources and Services Administration (HRSA) of MUHC's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, MUHC qualifies for the 340B Program as a disproportionate share hospital and has participated in the 340B Program since 1993.

Through the audit process, HRSA found that MUHC was not in compliance with the 340B Program and responsible for repayment as a result of the following finding(s):

340B drugs were not properly accumulated. MUHC did not have adequate controls in place to ensure proper accumulation and prevention of diversion of 340B drugs, as prohibited by 42 USC 256b(a)(5)(B).

MUHC has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from MUHC and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact David Wolfrath at (573) 882-8630.

Sincerely,

Mitch L. Wasden, Ed.D.
Chief Executive Officer
MU Health Care